Date: 2014-12-04
Type of information: Milestone
Compound: Trisenox® (arsenic trioxide)
Company: CTI BioPharma - previously known as Cell Therapeutics (USA - WA) - Teva Pharmaceutical Industries (Israel)
Therapeutic area: Cancer - Oncology
Type agreement: milestone
Action mechanism: The mechanism of action of Trisenox® is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein PML-RAR alpha.
Disease: acute promyelocytic leukemia
Details: * On December 4, 2014, CTI BioPharma announced that it has received a $15 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for Trisenox® (arsenic trioxide). Trisenox® was acquired from CTI by Cephalon. Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for Trisenox® entered into with Cephalon under which CTI is eligible to receive up to an additional $80 million in payments upon achievement by Teva of specified sales and development milestones related to Trisenox®.
Financial terms:
Latest news:
